

(19) World Intellectual Property
Organization
International Bureau



551 054

(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/085635 A1

(51) International Patent Classification⁷: **C12N 7/04**,
A61K 39/00, 39/39, C12N 15/11

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(21) International Application Number:
PCT/EP2004/003164

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 25 March 2004 (25.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/457,348 26 March 2003 (26.03.2003) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,
LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

(71) Applicant (for all designated States except US): **CYTOS
BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 25,
CH-8952 Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BACHMANN**,
Martin, F. [CH/CH]; Goldackerweg 8, CH-8472 Seuzach
(CH). **MANOLOVA**, Vania [BG/CH]; Pestalozzistrasse 41,
CH-8032 Zurich (CH). **MELJERINK**, Edwin
[NL/CH]; Rebbbergstrasse 50, CH-8049 Zurich (CH).
PROBA, Karl, G. [DE/CH]; Tramstrasse 95, CH-8050
Zurich (CH). **SCHWARZ**, Katrin [DE/CH]; Alter Zürich-
weg 31, CH-8952 Schlieren (CH).

(74) Agent: **WICHMANN, Hendrik**; Isenbruck Bösl
Hörschler Wichmann Huhn, Prinzregentenstr. 68, 81675
München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **MELAN-A PEPTIDE ANALOGUE-VIRUS-LIKE-PARTICLE CONJUGATES**

(57) Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The inven-
tion provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in
particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA
linked thereto. Such CpGVLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and
T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the
VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA
peptide analogues are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines
for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

WO 2004/085635 A1